A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2017
At a glance
- Drugs GBR 830 (Primary)
- Indications Atopic dermatitis; Coeliac disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals S.A.
- 04 Aug 2017 Status changed from recruiting to completed.
- 31 Jul 2017 Results of this study published in the Glenmark Pharmaceuticals Media Release
- 31 Jul 2017 According to a Glenmark Pharmaceuticals media release,Glenmark plans to submit result data for presentation at upcoming scientific meetings and publication in a peer-reviewed journal.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History